ESMO shared a post on LinkedIn:
“Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of Early Testing patients for BRCA and HRR mutations.
Read the opinion by Elena Castro in the ESMO Daily Reporter where she discusses how findings from both trials highlight the importance of identifying genetic alterations in metastatic hormone-sensitive prostate cancer (mHSPC) to tailor therapeutic options to our patients.”
Read Full Article on ESMO Daily Reporter.
More posts featuring ESMO on OncoDaily.